Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
Clinical Trial
. 2005 May;89(5):533-6.
doi: 10.1136/bjo.2003.037192.

Anti-TNF-alpha therapy for sight threatening uveitis

E W Lindstedt  1 , G S Baarsma, R W A M Kuijpers, P M van Hagen
Affiliations
Clinical Trial

Anti-TNF-alpha therapy for sight threatening uveitis

E W Lindstedt et al. Br J Ophthalmol. 2005 May.

Abstract

Aim: To describe the effect of additional treatment with anti-TNF-alpha therapy in a case series of 13 patients with serious sight threatening uveitis.

Methods: 13 patients with serious sight threatening uveitis were included, of whom six had Behçet's disease, five had idiopathic posterior uveitis, one had sarcoidosis, and one birdshot retinochoroiditis. Onset and course of ocular inflammation, inflammatory signs, and visual acuity were assessed. Patients were treated with 200 mg (approximately 3 mg/kg) infliximab infusion. Repeat infusions were given based on clinical response.

Results: Infliximab treatment resulted in an effective suppression of ocular inflammation in all patients. In patients with non-Behcet's disease uveitis visual acuity in six out of eight improved or was stable. In patients with Behcet's disease visual acuity in five out of six improved or was stable.

Conclusion: Anti-TNF-alpha treatment may be of value in the treatment of uveitis, and in patients with Behçet's disease, leading to suppression of ocular inflammation, vasculitis, and improvement of vision in the majority. Based on these results a controlled masked study is warranted.

PubMed Disclaimer

References

    1. De Vos AF, Klaren VN, Kijlstra. Expression of multiple cytokines and IL-1RA in the uvea and retina during endotoxin-induced uveitis in the rat. Invest Ophthalmol Vis Sci 1994;35:3873–83. - PubMed
    1. Okada AA, Sakai J, Usui M, et al. Intraocular cytokine quantification of experimental autoimmune uveoretinitis in rats. Ocul Immunol Inflamm 1998;6:111–20. - PubMed
    1. Nakamura S, Yamakawa T, Sugita M, et al. The role of tumor necrosis factor-alpha in the induction of experimental uveoretinitis in mice. Invest Ophthalmol Vis Sci 1994;35:3884–9. - PubMed
    1. Dick AD, Duncan L, Hale G, et al. Neutralizing TNF-alpha activity modulates T-cell phenotype function in experimental autoimmune uveoretinitis. J Autoimmun 1998;11:255–64. - PubMed
    1. Robertson M, Liversidge J, Forrester JV, et al. Neutralizing tumor necrosis factor-alpha activity suppresses activation of infiltrating macrophages in experimental autoimmune uveoretinitis. Invest Ophthalmol Vis Sci 2003;44:3034–41. - PubMed

Publication types